|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2011-8-9
|
|
pubmed:abstractText |
The augmented BFM regimen improves outcome for children with NCI high acute lymphoblastic leukemia (ALL). Patient age, sex, and presenting white blood cell count (WBC) can be used to identify a subset of approximately 12% of children with B-precursor ALL that had a 5-year continuous complete remission (CCR) rate of only about 50% on earlier Pediatric Oncology Group (POG) trials.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1545-5017
|
|
pubmed:author |
pubmed-author:BlachLaurieL,
pubmed-author:BorowitzMichael JMJ,
pubmed-author:BowmanW PaulWP,
pubmed-author:CamittaBruce MBM,
pubmed-author:CarrollAndrew JAJ,
pubmed-author:CarrollWilliam LWL,
pubmed-author:DevidasMeenakshiM,
pubmed-author:HungerStephen PSP,
pubmed-author:LarsenEric LEL,
pubmed-author:LindaStephen BSB,
pubmed-author:PullenD JeanetteDJ,
pubmed-author:ShusterJonathanJ,
pubmed-author:WillmanCheryl LCL,
pubmed-author:WinickNaomiN
|
|
pubmed:copyrightInfo |
Copyright © 2011 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
569-77
|
|
pubmed:meshHeading |
pubmed-meshheading:21360654-6-Mercaptopurine,
pubmed-meshheading:21360654-Adolescent,
pubmed-meshheading:21360654-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21360654-Asparaginase,
pubmed-meshheading:21360654-Child,
pubmed-meshheading:21360654-Child, Preschool,
pubmed-meshheading:21360654-Cyclophosphamide,
pubmed-meshheading:21360654-Cytarabine,
pubmed-meshheading:21360654-Daunorubicin,
pubmed-meshheading:21360654-Dexamethasone,
pubmed-meshheading:21360654-Female,
pubmed-meshheading:21360654-Humans,
pubmed-meshheading:21360654-Infant,
pubmed-meshheading:21360654-Kaplan-Meier Estimate,
pubmed-meshheading:21360654-Male,
pubmed-meshheading:21360654-Methotrexate,
pubmed-meshheading:21360654-Neoplasm, Residual,
pubmed-meshheading:21360654-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:21360654-Prednisone,
pubmed-meshheading:21360654-Risk Factors,
pubmed-meshheading:21360654-Thioguanine,
pubmed-meshheading:21360654-Treatment Outcome,
pubmed-meshheading:21360654-Vincristine
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
|
|
pubmed:affiliation |
Cook Children's Hospital, Fort Worth, Texas, USA.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, N.I.H., Extramural
|
